An overview of the latest price list details of olaparib targeted drugs

Olaparib is one of the PARP inhibitors currently widely used worldwide, and its indications cover a variety of solid tumors carrying BRCA or HRR gene mutations. In China, Lynparza has been approved for marketing by the National Medical Products Administration (NMPA) and has been included in the Class B National Medical Insurance List. Its scope of application includes: maintenance treatment of platinum-sensitive recurrent ovarian cancer, and targeted therapy of BRCA-mutated metastatic breast cancer. All indications require genetic testing to confirm the existence of relevant mutations before they can be included in the scope of medical insurance payment.

In terms of drug specifications, the main specifications of olaparib original drug (trade name: Lynparza) available in the domestic market are 100mg (7 plates per box, 8 tablets per plate) and 150mg (56 tablets per box). The retail price before medical insurance is about 6,000 to 7,000 yuan. Depending on local medical insurance policies, the price paid by patients after medical insurance will vary.

In international markets, such as the United States, Europe and other countries, the price of Lynparza is significantly higher than that in China.The price of 56 tablets of 150 mg may be close to US$8,000. Therefore, some patients choose to purchase generic drugs from overseas markets. For example, the price of generic drugs produced in Bangladesh, Laos and other places is more affordable. For example, the price of 112 tablets of 50mg is about 2,000-3,000 yuan. However, these drugs can only be obtained by individuals purchasing drugs overseas. They need to be used with caution to ensure that the sources are legal and reliable.

To sum up, the current price of Lynparza in China has been significantly reduced, especially with the support of medical insurance, it has strong accessibility. Although generic drugs are cheap, they still need to be used in conjunction with doctor's advice and purchased through regular channels to ensure efficacy and safety. For patients, the choice of olaparib treatment should be based on a comprehensive evaluation of genetic testing results, financial ability, and treatment goals.

Reference materials:https://www.lynparza.com/